Last week our colleagues Marianne Koliana and Gustav Lindved attended the Microbiome Connect Conference in Boston.
A particularly important topic discussed throughout the conference was engraftment analysis for fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs).
This was highlighted by our collaborator Ken Blount, CSO at Rebiotix Inc, a Ferring Company, making an incredibly enlightening presentation of our joint work for understanding microbiome restoration and engraftment in their phase 3 clinical trial of RBX2660. We are extremely excited about this collaboration and grateful for the opportunity for supporting a company like Rebiotix spearheading the development of microbiome therapeutics.
Developing efficient and safe microbiome therapeutics demands a truly deep understanding of the microbiome. Clonal-level engraftment technology provides unparalleled insights and understanding for microbiome therapeutics in clinical development.
Would you like to know more? Connect with us to discuss your project!